Lagging demand for the iPhone X and reports from smartphone chipmakers of decreased orders has some analysts predicting that Apple will retire its most expensive phone.
Mirabaud analyst [Neil Campling](https://www.cnbc.com/2018/04/20/apple-iphone-x-discontinued-this-year-analyst-says.html) said he anticipates the iPhone X will likely be discontinued this year.
According to Sascha Segan, lead analyst for PCMag.com, that's not going to happen. Instead, Segan said that Apple would launch new iPhones in the fall and the X would live on as the premium iPhone on the market.
"We are going to do a little flipping here," said Segan. "You have this prestige position where the X is, and then the 11 and then the 12 possibly."
When asked if the X is worthy of that prestige position, Segan said, "No, I never thought the iPhone X was worth a thousand dollars."
The iPhone X is still the most profitable iPhone despite underwhelming demand. Segan said that Apple was testing consumers' limits with the iPhone X. But he thinks the company will keep pushing those limits.
For full interview, [click here](https://cheddar.com/videos/iphone-x-dead).
President Joe Biden and Chinese President Xi Jinping have discussed Taiwan, artificial intelligence and security issues in a call meant to demonstrate a return to regular leader-to-leader dialogue between the two powers.
April is Earth month, and while the green revolution might feel far away, the founder of climate VC Siam Capital says it’s on it’s way, and, even better: it won't cost you more.
From snow in April to heatwaves in December, it’s hard to plan a trip in a climate change world. Startup Sensible Weather thinks weather-based travel reimbursements are the solution.
Between corporate debt and the widening gap between ‘the haves and the have nots,’ there are reasons to be cautious about the economy, even with interest rate cuts on their way.
If the A.I. hype hasn’t given you enough of a reason to be excited (and a little terrified), the CEO of Zapata AI says the next frontier is designing bridges or creating pharmaceutical drugs.
